Advertisement
Advertisement
NNVC
NanoViricides Inc.
1.42
USDSponsored
+0.02
+1.43%
Aug 07, 15:40 UTC -4
Closed
After-Market
1.45
+0.03
+2.11%
NNVC Earnings Reports
Positive Surprise Ratio
NNVC beat 13 of 14 last estimates.
93%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
NanoViricides Inc. earnings per share and revenue
On May 13, 2026, NNVC reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.13 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
Guardian Pharmacy Services, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.28
Surprise
+3.76%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
FAQ
What were NanoViricides Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, NanoViricides Inc. reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to NanoViricides Inc.'s Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is NanoViricides Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for NanoViricides Inc.'s next earnings report?
Based on --
analysts, NanoViricides Inc. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement